OPTN

OptiNose, Inc.

OPTN | $0.8951 -3.51% -3.64% 650K

(0.0% 1d) (-45.8% 1m) (-51.1% 1y) (0.0% 2d) (-8.8% 3d) (-21.8% 7d) (18.83% volume)
Earnings Calendar: 2024-03-05
Market Cap: $ 100,834,572
http://www.optinose.com
Sec Filling | Patents | 224 employees

(US) OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

msa

add to watch list Paper trade email alert is off

Press-releases

Optinose to Present at the Needham Virtual Healthcare Conference
Published: 2024-04-04 (Crawled : 20:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -32.12% | O: 1.46% H: 0.72% C: -5.04%
conference

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Published: 2024-03-15 (Crawled : 20:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| Email alert Add to watchlist
fda first xhance approved treatment

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Published: 2024-03-07 (Crawled : 12:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -46.86% | O: -4.0% H: 5.95% C: 2.38%
year financial

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Published: 2024-02-29 (Crawled : 22:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -47.75% | O: -0.56% H: 7.91% C: 7.91%
financial results

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Published: 2024-01-18 (Crawled : 17:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -28.46% | O: -0.77% H: 4.63% C: 1.55%
xhance publication program trial

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
Published: 2023-12-06 (Crawled : 12:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -36.73% | O: -17.01% H: 1.64% C: 0.82%
fda xhance drug review extension application

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-22 (Crawled : 14:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -23.77% | O: 0.0% H: 2.46% C: 0.41%
conference

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
Published: 2023-11-09 (Crawled : 12:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -25.0% | O: 11.29% H: 0.0% C: -11.59%
financial results

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
Published: 2023-10-27 (Crawled : 12:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -21.85% | O: 0.0% H: 3.36% C: 2.52%
financial results

Optinose to Present at the 2023 Cantor Global Healthcare Conference
Published: 2023-09-22 (Crawled : 13:00) - globenewswire.com
OPTN | $0.8951 -3.51% -3.64% 650K

Health Services

| -25.0% | O: 0.81% H: 4.0% C: 0.8%
conference global

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001494650-24-000038	4	2024-03-19	2024-03-18	Sell	S	2345	143988
0001494650-24-000036	4	2024-03-19	2024-03-18	Sell	S	15059	602268
0001494650-24-000036	4	2024-03-19	2024-03-15	Buy	A	3816	617327
0001494650-24-000034	4	2024-03-19	2024-03-18	Sell	S	19198	1331278
0001494650-24-000034	4	2024-03-19	2024-03-15	Buy	A	6114	1350476